Why Intellia Therapeutics Stock Is Soaring Today

Intellia Therapeutics Inc NTLA is trading significantly higher Monday morning after the company announced positive clinical data for its CRISPR therapy.

What Happened: Intellia and Regeneron Pharmaceuticals Inc REGN reported positive interim data from an ongoing Phase 1 clinical study of the in vivo genome editing candidate NTLA-2001. NTLA-2001 is being developed as a single-dose treatment for transthyretin amyloidosis. 

“These are the first ever clinical data suggesting that we can precisely edit target cells within the body to treat genetic disease with a single intravenous infusion of CRISPR. The interim results support our belief that NTLA-2001 has the potential to halt and reverse the devastating complications of ATTR amyloidosis with a single dose,” John Leonard, president and CEO of Intellia, said in a statement. 

Intellia Analysts React: Multiple analyst firms raised price targets following the announcement:

  • Chardan Capital analyst Geulah Livshits maintained Intellia Therapeutics with a Buy rating and raised the price target from $85 to $130.
  • HC Wainwright & Co. analyst Michael King maintained Intellia Therapeutics with a Buy rating and raised the price target from $111 to $171.
  • Roth Capital analyst Tony Butler maintained Intellia Therapeutics with a Buy rating and raised the price target from $80 to $110.
  • Truist Securities analyst Joon Lee maintained Intellia Therapeutics with a Buy rating and raised the price target from $80 to $160.
  • Goldman Sachs analyst Salveen Richter maintained Intellia Therapeutics with a Buy rating and raised the price target from $115 to $163.
  • Barclays analyst Gena Wang maintained Intellia Therapeutics with an Overweight rating and raised the price target from $88 to $134.

See Also: 24 Stocks Moving in Monday's Pre-Market Session

NTLA Price Action: Intellia is making a new 52-week high in premarket trading today.

At last check Monday, the stock was up 52.46% at $135.43.

Photo courtesy of Intellia.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorBiotechPrice TargetReiterationAnalyst RatingsMoversTrading IdeasGeneralGena WangGeulah LivshitsJohn LeonardJoon LeeMichael KingSalveen RichterTony Butlerwhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!